Download PDF
Semin Respir Crit Care Med 2011; 32(2): 195-205
DOI: 10.1055/s-0031-1275532
© Thieme Medical Publishers

Reducing Mortality in Severe Sepsis and Septic Shock

Andrew T. Levinson1 , Brian P. Casserly1 , Mitchell M. Levy1
  • 1Division of Pulmonary, Critical Care, and Sleep Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island
Further Information

Publication History

Publication Date:
19 April 2011 (online)

    Permissions and Reprints

ABSTRACT

Severe sepsis is one of the most common reasons for critically ill patients to be admitted to an intensive care unit (ICU) and has very high associated morbidity and mortality. The Surviving Sepsis Campaign was initiated with the hope that mortality might be reduced by standardizing care informed by data from an increasing number of clinical trials. Important methods for reducing mortality identified by recent studies include aggressive fluid resuscitation, early goal-directed therapy (EGDT), early administration of antibiotics, and the administration of activated protein C to eligible patients.

KEYWORDS

Sepsis - septic shock - critical care - Surviving Sepsis Campaign

REFERENCES

  • 1 Linde-Zwirble W T, Angus D C. Severe sepsis epidemiology: sampling, selection, and society.  Crit Care. 2004;  8 (4) 222-226
    CrossrefPubMedGoogle Scholar
  • 2 Martin G S, Mannino D M, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000.  N Engl J Med. 2003;  348 (16) 1546-1554
    CrossrefPubMedGoogle Scholar
  • 3 Angus D C, Linde-Zwirble W T, Lidicker J, Clermont G, Carcillo J, Pinsky M R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.  Crit Care Med. 2001;  29 (7) 1303-1310
    CrossrefPubMedGoogle Scholar
  • 4 Vincent J L, Sakr Y, Sprung C L Sepsis Occurrence in Acutely Ill Patients Investigators et al. Sepsis in European intensive care units: results of the SOAP study.  Crit Care Med. 2006;  34 (2) 344-353
    CrossrefPubMedGoogle Scholar
  • 5 Lundberg J S, Perl T M, Wiblin T et al.. Septic shock: an analysis of outcomes for patients with onset on hospital wards versus intensive care units.  Crit Care Med. 1998;  26 (6) 1020-1024
    CrossrefPubMedGoogle Scholar
  • 6 Nguyen H B, Rivers E P, Havstad S et al.. Critical care in the emergency department: a physiologic assessment and outcome evaluation.  Acad Emerg Med. 2000;  7 (12) 1354-1361
    CrossrefPubMedGoogle Scholar
  • 7 Tarassenko L, Hann A, Young D. Integrated monitoring and analysis for early warning of patient deterioration.  Br J Anaesth. 2006;  97 (1) 64-68
    CrossrefPubMedGoogle Scholar
  • 8 McIntyre L A, Fergusson D, Cook D J Canadian Critical Care Trials Group et al. Fluid resuscitation in the management of early septic shock (FINESS): a randomized controlled feasibility trial.  Can J Anaesth. 2008;  55 (12) 819-826
    CrossrefPubMedGoogle Scholar
  • 9 Reade M C, Huang D T, Bell D British Association for Emergency Medicine et al. Variability in management of early severe sepsis.  Emerg Med J. 2010;  27 (2) 110-115
    CrossrefPubMedGoogle Scholar
  • 10 Antman E M, Anbe D T, Armstrong P W American College of Cardiology et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction).  J Am Coll Cardiol. 2004;  44 (3) 671-719
    CrossrefPubMedGoogle Scholar
  • 11 Annane D, Bellissant E, Bollaert P E et al.. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review.  JAMA. 2009;  301 (22) 2362-2375
    CrossrefPubMedGoogle Scholar
  • 12 van Ruler O, Schultz M J, Reitsma J B, Gouma D J, Boermeester M A. Has mortality from sepsis improved and what to expect from new treatment modalities: review of current insights.  Surg Infect (Larchmt). 2009;  10 (4) 339-348
    CrossrefPubMedGoogle Scholar
  • 13 Byrnes M C, Beilman G J. Adjunctive measures for treating surgical infections and sepsis.  Surg Clin North Am. 2009;  89 (2) 349-363, viii
    CrossrefPubMedGoogle Scholar
  • 14 Dellinger R P, Levy M M, Carlet J M International Surviving Sepsis Campaign Guidelines Committee et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.  Crit Care Med. 2008;  36 (1) 296-327
    CrossrefPubMedGoogle Scholar
  • 15 Dellinger R P, Carlet J M, Masur H Surviving Sepsis Campaign Management Guidelines Committee et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.  Crit Care Med. 2004;  32 (3) 858-873 [Erratum in: Crit Care Med 2004;32(6):1448. Dosage error in article text. Crit Care Med 2004;32(10):2169–2170]
    CrossrefPubMedGoogle Scholar
  • 16 Cabana M D, Rand C S, Powe N R et al.. Why don't physicians follow clinical practice guidelines? A framework for improvement.  JAMA. 1999;  282 (15) 1458-1465
    CrossrefPubMedGoogle Scholar
  • 17 Kalil A C, Sun J. Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis.  PLoS ONE. 2008;  3 (5) e2291
    CrossrefPubMedGoogle Scholar
  • 18 Pronovost P J, Berenholtz S M, Needham D M. Translating evidence into practice: a model for large scale knowledge translation.  BMJ. 2008;  337 A1714
    CrossrefPubMedGoogle Scholar
  • 19 Vandijck D M, Labeau S O, Blot S I. Facilitating clinician adherence to guidelines in the intensive care unit.  Crit Care Med. 2008;  36 (2) 655
    PubMedGoogle Scholar
  • 20 Berwick D M. The science of improvement.  JAMA. 2008;  299 (10) 1182-1184
    CrossrefPubMedGoogle Scholar
  • 21 Severe sepsis bundles. Available at: http://www.survivingsepsis.org/Bundles/Pages/default.aspx Accessed March 29, 2011
    Google Scholar
  • 22 Annane D, Cariou A, Maxime V COIITSS Study Investigators et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial.  JAMA. 2010;  303 (4) 341-348
    CrossrefPubMedGoogle Scholar
  • 23 Sprung C L, Annane D, Keh D CORTICUS Study Group et al. Hydrocortisone therapy for patients with septic shock.  N Engl J Med. 2008;  358 (2) 111-124
    CrossrefPubMedGoogle Scholar
  • 24 Casserly B, Read R, Levy M M. Hemodynamic monitoring in sepsis.  Crit Care Clin. 2009;  25 (4) 803-823, ix
    CrossrefPubMedGoogle Scholar
  • 25 Shoemaker W C. A new approach to physiology, monitoring, and therapy of shock states.  World J Surg. 1987;  11 (2) 133-146
    CrossrefPubMedGoogle Scholar
  • 26 Snell R J, Parrillo J E. Cardiovascular dysfunction in septic shock.  Chest. 1991;  99 (4) 1000-1009
    CrossrefPubMedGoogle Scholar
  • 27 Parrillo J E, Parker M M, Natanson C et al.. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy.  Ann Intern Med. 1990;  113 (3) 227-242
    CrossrefPubMedGoogle Scholar
  • 28 Barochia A V, Cui X, Vitberg D et al.. Bundled care for septic shock: an analysis of clinical trials.  Crit Care Med. 2010;  38 (2) 668-678
    CrossrefPubMedGoogle Scholar
  • 29 Arnold R C, Shapiro N I, Jones A E Emergency Medicine Shock Research Network (EMShockNet) Investigators et al. Multicenter study of early lactate clearance as a determinant of survival in patients with presumed sepsis.  Shock. 2009;  32 (1) 35-39
    CrossrefPubMedGoogle Scholar
  • 30 Parrillo J E. Pathogenetic mechanisms of septic shock.  N Engl J Med. 1993;  328 (20) 1471-1477
    CrossrefPubMedGoogle Scholar
  • 31 Partrick D A, Bensard D D, Janik J S, Karrer F M. Is hypotension a reliable indicator of blood loss from traumatic injury in children?.  Am J Surg. 2002;  184 (6) 555-559, discussion 559–560
    CrossrefPubMedGoogle Scholar
  • 32 Beal A L, Cerra F B. Multiple organ failure syndrome in the 1990s: systemic inflammatory response and organ dysfunction.  JAMA. 1994;  271 (3) 226-233
    CrossrefPubMedGoogle Scholar
  • 33 Perel A. Bench-to-bedside review: the initial hemodynamic resuscitation of the septic patient according to Surviving Sepsis Campaign guidelines—does one size fit all?.  Crit Care. 2008;  12 (5) 223
    CrossrefPubMedGoogle Scholar
  • 34 Carroll G C, Snyder J V. Hyperdynamic severe intravascular sepsis depends on fluid administration in cynomolgus monkey.  Am J Physiol. 1982;  243 (1) R131-R141
    PubMedGoogle Scholar
  • 35 Rivers E, Nguyen B, Havstad S Early Goal-Directed Therapy Collaborative Group et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock.  N Engl J Med. 2001;  345 (19) 1368-1377
    CrossrefPubMedGoogle Scholar
  • 36 He Z Y, Gao Y, Wang X R, Hang Y N. Clinical evaluation of execution of early goal directed therapy in septic shock [in Chinese].  Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007;  19 (1) 14-16
    PubMedGoogle Scholar
  • 37 Kortgen A, Niederprüm P, Bauer M. Implementation of an evidence-based “standard operating procedure” and outcome in septic shock.  Crit Care Med. 2006;  34 (4) 943-949
    CrossrefPubMedGoogle Scholar
  • 38 Sebat F, Johnson D, Musthafa A A et al.. A multidisciplinary community hospital program for early and rapid resuscitation of shock in nontrauma patients.  Chest. 2005;  127 (5) 1729-1743
    CrossrefPubMedGoogle Scholar
  • 39 Shapiro N I, Howell M D, Talmor D et al.. Implementation and outcomes of the Multiple Urgent Sepsis Therapies (MUST) protocol.  Crit Care Med. 2006;  34 (4) 1025-1032
    CrossrefPubMedGoogle Scholar
  • 40 Trzeciak S, Dellinger R P, Abate N L et al.. Translating research to clinical practice: a 1-year experience with implementing early goal-directed therapy for septic shock in the emergency department.  Chest. 2006;  129 (2) 225-232
    CrossrefPubMedGoogle Scholar
  • 41 Huang D T, Clermont G, Dremsizov T T, Angus D C. ProCESS Investigators . Implementation of early goal-directed therapy for severe sepsis and septic shock: a decision analysis.  Crit Care Med. 2007;  35 (9) 2090-2100
    CrossrefPubMedGoogle Scholar
  • 42 Guyatt G, Gutterman D, Baumann M H et al.. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force.  Chest. 2006;  129 (1) 174-181
    CrossrefPubMedGoogle Scholar
  • 43 Marik P E, Varon J. Goal-directed therapy for severe sepsis.  N Engl J Med. 2002;  346 (13) 1025-1026, author reply 1025–1026
    CrossrefPubMedGoogle Scholar
  • 44 Choi P T, Yip G, Quinonez L G, Cook D J. Crystalloids vs. colloids in fluid resuscitation: a systematic review.  Crit Care Med. 1999;  27 (1) 200-210
    CrossrefPubMedGoogle Scholar
  • 45 Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. SAFE Study Investigators . A comparison of albumin and saline for fluid resuscitation in the intensive care unit.  N Engl J Med. 2004;  350 (22) 2247-2256
    CrossrefPubMedGoogle Scholar
  • 46 Bakker J, Coffernils M, Leon M, Gris P, Vincent J L. Blood lactate levels are superior to oxygen-derived variables in predicting outcome in human septic shock.  Chest. 1991;  99 (4) 956-962
    CrossrefPubMedGoogle Scholar
  • 47 Mikkelsen M E, Miltiades A N, Gaieski D F et al.. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock.  Crit Care Med. 2009;  37 (5) 1670-1677
    CrossrefPubMedGoogle Scholar
  • 48 Nguyen H B, Rivers E P, Knoblich B P et al.. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock.  Crit Care Med. 2004;  32 (8) 1637-1642
    CrossrefPubMedGoogle Scholar
  • 49 Nguyen H B, Loomba M, Yang J J et al.. Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock.  J Inflamm (Lond). 2010;  7 6
    CrossrefPubMedGoogle Scholar
  • 50 Edwards J D. Oxygen transport in cardiogenic and septic shock.  Crit Care Med. 1991;  19 (5) 658-663
    CrossrefPubMedGoogle Scholar
  • 51 Bauer P, Reinhart K, Bauer M. Significance of venous oximetry in the critically ill.  Med Intensiva. 2008;  32 (3) 134-142
    CrossrefPubMedGoogle Scholar
  • 52 Reinhart K, Kuhn H J, Hartog C, Bredle D L. Continuous central venous and pulmonary artery oxygen saturation monitoring in the critically ill.  Intensive Care Med. 2004;  30 (8) 1572-1578
    PubMedGoogle Scholar
  • 53 Varpula M, Tallgren M, Saukkonen K, Voipio-Pulkki L M, Pettilä V. Hemodynamic variables related to outcome in septic shock.  Intensive Care Med. 2005;  31 (8) 1066-1071
    CrossrefPubMedGoogle Scholar
  • 54 Bellomo R, Reade M C, Warrillow S J. The pursuit of a high central venous oxygen saturation in sepsis: growing concerns.  Crit Care. 2008;  12 (2) 130
    CrossrefPubMedGoogle Scholar
  • 55 Reinhart K, Bloos F. The value of venous oximetry.  Curr Opin Crit Care. 2005;  11 (3) 259-263
    CrossrefPubMedGoogle Scholar
  • 56 Kumar A, Anel R, Bunnell E et al.. Pulmonary artery occlusion pressure and central venous pressure fail to predict ventricular filling volume, cardiac performance, or the response to volume infusion in normal subjects.  Crit Care Med. 2004;  32 (3) 691-699
    CrossrefPubMedGoogle Scholar
  • 57 Marik P E, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares.  Chest. 2008;  134 (1) 172-178
    CrossrefPubMedGoogle Scholar
  • 58 Hadian M, Pinsky M R. Functional hemodynamic monitoring.  Curr Opin Crit Care. 2007;  13 (3) 318-323
    CrossrefPubMedGoogle Scholar
  • 59 Sakr Y, Chierego M, Piagnerelli M et al.. Microvascular response to red blood cell transfusion in patients with severe sepsis.  Crit Care Med. 2007;  35 (7) 1639-1644
    CrossrefPubMedGoogle Scholar
  • 60 Marshall J C, al Naqbi A. Principles of source control in the management of sepsis.  Crit Care Clin. 2009;  25 (4) 753-768, viii–ix
    CrossrefPubMedGoogle Scholar
  • 61 Houck P M, Bratzler D W, Nsa W, Ma A, Bartlett J G. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.  Arch Intern Med. 2004;  164 (6) 637-644
    CrossrefPubMedGoogle Scholar
  • 62 Kumar A, Haery C, Paladugu B et al.. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels.  J Infect Dis. 2006;  193 (2) 251-258
    CrossrefPubMedGoogle Scholar
  • 63 Gaieski D F, Mikkelsen M E, Band R A et al.. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department.  Crit Care Med. 2010;  38 (4) 1045-1053
    CrossrefPubMedGoogle Scholar
  • 64 Zubert S, Funk D J, Kumar A. Antibiotics in sepsis and septic shock: like everything else in life, timing is everything.  Crit Care Med. 2010;  38 (4) 1211-1212
    CrossrefPubMedGoogle Scholar
  • 65 Ibrahim E H, Sherman G, Ward S, Fraser V J, Kollef M H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.  Chest. 2000;  118 (1) 146-155
    CrossrefPubMedGoogle Scholar
  • 66 Micek S T, Welch E C, Khan J et al.. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: a retrospective analysis.  Antimicrob Agents Chemother. 2010;  54 (5) 1742-1748
    CrossrefPubMedGoogle Scholar
  • 67 Hollenberg S M. Inotrope and vasopressor therapy of septic shock.  Crit Care Clin. 2009;  25 (4) 781-802, ix
    CrossrefPubMedGoogle Scholar
  • 68 Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?.  Chest. 1993;  103 (6) 1826-1831
    CrossrefPubMedGoogle Scholar
  • 69 De Backer D, Biston P, Devriendt J SOAP II Investigators et al. Comparison of dopamine and norepinephrine in the treatment of shock.  N Engl J Med. 2010;  362 (9) 779-789
    CrossrefPubMedGoogle Scholar
  • 70 Parrillo J E. Septic shock—vasopressin, norepinephrine, and urgency.  N Engl J Med. 2008;  358 (9) 954-956
    CrossrefPubMedGoogle Scholar
  • 71 Russell J A, Walley K R, Singer J VASST Investigators et al. Vasopressin versus norepinephrine infusion in patients with septic shock.  N Engl J Med. 2008;  358 (9) 877-887
    CrossrefPubMedGoogle Scholar
  • 72 Russell J A, Walley K R, Gordon A C Dieter Ayers for the Vasopressin and Septic Shock Trial Investigators et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock.  Crit Care Med. 2009;  37 (3) 811-818
    CrossrefPubMedGoogle Scholar
  • 73 Fourrier F. Recombinant human activated protein C in the treatment of severe sepsis: an evidence-based review.  Crit Care Med. 2004;  32 (11, Suppl) S534-S541
    CrossrefPubMedGoogle Scholar
  • 74 Castellino F J, Ploplis V A. The protein C pathway and pathologic processes.  J Thromb Haemost. 2009;  7 (Suppl 1) 140-145
    CrossrefPubMedGoogle Scholar
  • 75 Mosnier L O, Zlokovic B V, Griffin J H. The cytoprotective protein C pathway.  Blood. 2007;  109 (8) 3161-3172
    CrossrefPubMedGoogle Scholar
  • 76 Shorr A F, Bernard G R, Dhainaut J F et al.. Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome.  Crit Care. 2006;  10 (3) R92
    CrossrefPubMedGoogle Scholar
  • 77 Fisher Jr C J, Yan S B. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases.  Crit Care Med. 2000;  28 (9, Suppl) S49-S56
    CrossrefPubMedGoogle Scholar
  • 78 Bernard G R, Vincent J L, Laterre P F Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group et al. Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344 (10) 699-709
    CrossrefPubMedGoogle Scholar
  • 79 Beutler B. Innate immunity: an overview.  Mol Immunol. 2004;  40 (12) 845-859
    CrossrefPubMedGoogle Scholar
  • 80 Vincent J L, Bernard G R, Beale R et al.. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial enhance: further evidence for survival and safety and implications for early treatment.  Crit Care Med. 2005;  33 (10) 2266-2277
    CrossrefPubMedGoogle Scholar
  • 81 Abraham E, Laterre P F, Garg R Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.  N Engl J Med. 2005;  353 (13) 1332-1341
    CrossrefPubMedGoogle Scholar
  • 82 Lindenauer P K, Rothberg M B, Nathanson B H, Pekow P S, Steingrub J S. Activated protein C and hospital mortality in septic shock: a propensity-matched analysis.  Crit Care Med. 2010;  38 (4) 1101-1107
    CrossrefPubMedGoogle Scholar
  • 83 Annane D, Bellissant E. Prognostic value of cortisol response in septic shock.  JAMA. 2000;  284 (3) 308-309
    CrossrefPubMedGoogle Scholar
  • 84 Bone R C, Fisher Jr C J, Clemmer T P, Slotman G J, Metz C A, Balk R A. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.  N Engl J Med. 1987;  317 (11) 653-658
    CrossrefPubMedGoogle Scholar
  • 85 Cronin L, Cook D J, Carlet J et al.. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature.  Crit Care Med. 1995;  23 (8) 1430-1439
    CrossrefPubMedGoogle Scholar
  • 86 Minneci P C, Deans K J, Banks S M, Eichacker P Q, Natanson C. Corticosteroids for septic shock.  Ann Intern Med. 2004;  141 (9) 742-743
    PubMedGoogle Scholar
  • 87 Annane D, Sébille V, Charpentier C et al.. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.  JAMA. 2002;  288 (7) 862-871 [Erratum in: JAMA 2008;300(14):1652. Chaumet-Riffaut, Philippe corrected to Chaumet-Riffaud, Philippe]
    CrossrefPubMedGoogle Scholar
  • 88 Sligl W I, Milner Jr D A, Sundar S, Mphatswe W, Majumdar S R. Safety and efficacy of corticosteroids for the treatment of septic shock: a systematic review and meta-analysis.  Clin Infect Dis. 2009;  49 (1) 93-101
    CrossrefPubMedGoogle Scholar
  • 89 van den Berghe G, Wouters P, Weekers F et al.. Intensive insulin therapy in the critically ill patients.  N Engl J Med. 2001;  345 (19) 1359-1367
    CrossrefPubMedGoogle Scholar
  • 90 Van den Berghe G, Wilmer A, Hermans G et al.. Intensive insulin therapy in the medical ICU.  N Engl J Med. 2006;  354 (5) 449-461
    CrossrefPubMedGoogle Scholar
  • 91 Wiener R S, Wiener D C, Larson R J. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis.  JAMA. 2008;  300 (8) 933-944
    CrossrefPubMedGoogle Scholar
  • 92 Brunkhorst F M, Engel C, Bloos F German Competence Network Sepsis (SepNet) et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis.  N Engl J Med. 2008;  358 (2) 125-139
    CrossrefPubMedGoogle Scholar
  • 93 Finfer S, Chittock D R, Su S Y NICE-SUGAR Study Investigators et al. Intensive versus conventional glucose control in critically ill patients.  N Engl J Med. 2009;  360 (13) 1283-1297
    CrossrefPubMedGoogle Scholar
  • 94 Otero R M, Nguyen H B, Huang D T et al.. Early goal-directed therapy in severe sepsis and septic shock revisited: concepts, controversies, and contemporary findings.  Chest. 2006;  130 (5) 1579-1595
    CrossrefPubMedGoogle Scholar
  • 95 Castellanos-Ortega A, Suberviola B, García-Astudillo L A et al.. Impact of the Surviving Sepsis Campaign protocols on hospital length of stay and mortality in septic shock patients: results of a three-year follow-up quasi-experimental study.  Crit Care Med. 2010;  38 (4) 1036-1043
    CrossrefPubMedGoogle Scholar
  • 96 Levy M M, Dellinger R P, Townsend S R et al.. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis.  Intensive Care Med. 2010;  36 (2) 222-231
    CrossrefPubMedGoogle Scholar

Mitchell M LevyM.D. 

Division of Pulmonary and Critical Care Medicine, Rhode Island Hospital

593 Eddy St., Main 7, Providence, RI 02903

Email: Mitchell_Levy@brown.edu

      >